Journal article
Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study.
- Abstract:
-
Sulfonylureas are metabolized mainly by the cytochrome p450 2C9 (CYP2C9) enzyme. Two CYP2C9 variants--*2 (Arg144Cys) and *3 (Ile359Leu)--are associated with reduced enzyme activity and impaired substrate metabolism. We identified 1,073 incident users of sulfonylureas in Tayside, Scotland, and assessed the impact of the combined CYP2C9*2 and CYP2C9*3 genotypes on early and sustained sulfonylurea response. We found that patients with two copies of a loss-of-function allele were 3.4 times (P = 0...
Expand abstract
- Publication status:
- Published
Actions
Authors
Bibliographic Details
- Journal:
- Clinical pharmacology and therapeutics
- Volume:
- 87
- Issue:
- 1
- Pages:
- 52-56
- Publication date:
- 2010-01-01
- DOI:
- EISSN:
-
1532-6535
- ISSN:
-
0009-9236
- Source identifiers:
-
41507
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:41507
- UUID:
-
uuid:ac629ef8-d1cf-414c-883f-e50dd5912de8
- Local pid:
- pubs:41507
- Deposit date:
- 2012-12-19
Terms of use
- Copyright date:
- 2010
If you are the owner of this record, you can report an update to it here: Report update to this record